title: Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy.
abstract: Background One of the big challenges in onco-radiology is to find a reliable imaging method that may predict early response during the first cycles of any neoadjuvant chemotherapy. Purpose To evaluate the use of real-time harmonic contrast-enhanced ultrasound (CEUS) in predicting early response in breast cancer tumors under neoadjuvant chemotherapy (NAC) treatment. Material and Methods Nineteen consecutive patients with invasive breast cancer were evaluated with a bolus dose of 2.4 mL contrast agent using CEUS, before and after two cycles of epirubicin and docetaxel. The lognormal function was used for quantitative analysis of kinetic data to evaluate early response. Results There was statistically significant difference in time-to-peak ( tp) between responders and non-responders (two sample t-test, P = 0.027) where tpwas significantly longer at the week 5 than at the baseline scan among responders when compared to non-responders. Conclusion In-flow of intravascular contrast agent in tumors is significantly slower in responders at real-time harmonic CEUS, and might be effectively used for the evaluation of early response to chemotherapy in invasive breast cancer. However, further investigations in a larger and more heterogeneous population should be performed to corroborate the reliability of the method.
authors.affiliation: 1 Division of Radiology, Department of Breast Imaging: Bröstcentrum Södersjukhuset, Södersjukhuset, Stockholm, Sweden.
authors.forename: Ariel
authors.initials: A
authors.lastname: Saracco
authors.affiliation: 2 Department of Radiology, Barking, Havering and Redbridge University Hospitals NHS Trust, London, UK.
authors.forename: Botond K
authors.initials: BK
authors.lastname: Szabó
authors.affiliation: 3 Bolyai Institute, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary.|4 Department of Medical Physics and Informatics, Faculty of Medicine, University of Szeged, Szeged, Hungary.
authors.forename: Ervin
authors.initials: E
authors.lastname: Tánczos
authors.affiliation: 5 Department of Oncology, Karolinska Institutet, Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Jonas
authors.initials: J
authors.lastname: Bergh
authors.affiliation: 5 Department of Oncology, Karolinska Institutet, Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Thomas
authors.initials: T
authors.lastname: Hatschek
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001940:Breast / Q000000981:diagnostic imaging; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D003287:Contrast Media; D000077143:Docetaxel; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D015203:Reproducibility of Results; D043823:Taxoids / Q000627:therapeutic use; D016896:Treatment Outcome; D016217:Ultrasonography, Mammary / Q000379:methods*
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D003287:Contrast Media; D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin
keywords: Breast cancer; contrast agent; contrast-enhanced ultrasound; early response; microbubbles; neoadjuvant chemotherapy